
Lipocine (LPCN) Stock Forecast & Price Target
Lipocine (LPCN) Analyst Ratings
Bulls say
Lipocine Inc. is advancing its clinical-stage pipeline with LPCN 1154, an oral formulation of brexanolone that demonstrates a significant improvement in efficacy and safety compared to existing treatments, supported by a favorable safety profile with no reports of severe adverse events. The company’s strategic focus on drug delivery solutions, including its flagship product TLANDO and other promising candidates, positions it well within the biopharmaceutical sector. Despite a net loss of $3.2 million reported, there is optimism surrounding its potential for a 505(b)(2) new drug application submission, which could catalyze future financial growth and investment interest.
Bears say
Lipocine Inc. reported a net loss of $3.2 million in the third quarter of 2025, indicating ongoing financial challenges as the company navigates its clinical development stage. The company's prospects are overshadowed by significant risks associated with its lead product candidate, LPCN 1154, including potential failure in clinical trials, regulatory approval hurdles, and commercial viability issues such as reimbursement and competition. Additionally, concerns about dilution risk further exacerbate the negative outlook for Lipocine's stock, as these factors contribute to uncertainty and instability in the company's financial future.
This aggregate rating is based on analysts' research of Lipocine and is not a guaranteed prediction by Public.com or investment advice.
Lipocine (LPCN) Analyst Forecast & Price Prediction
Start investing in Lipocine (LPCN)
Order type
Buy in
Order amount
Est. shares
0 shares